Equetro

Chronic Pain, Bipolar Disorder, Bipolar Disorder + 6 more

Treatment

15 FDA approvals

20 Active Studies for Equetro

What is Equetro

Carbamazepine

The Generic name of this drug

Treatment Summary

Carbamazepine, also known as Tegretol, is a medication used to control seizures and treat pain caused by trigeminal neuralgia. It was first approved by the FDA in 1965 and is also prescribed to help manage the symptoms of bipolar disorder. It was the first anticonvulsant used to treat bipolar disorder.

Tegretol

is the brand name

image of different drug pills on a surface

Equetro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tegretol

Carbamazepine

1968

259

Approved as Treatment by the FDA

Carbamazepine, commonly known as Tegretol, is approved by the FDA for 15 uses like Partial Seizures With Secondary Generalization and Bipolar Disorder .

Partial Seizures With Secondary Generalization

Bipolar Disorder

Bipolar Disorder

Pain

Helps manage Pain

Common Cold

Trigeminal Neuralgia

Helps manage Trigeminal Neuralgia (TN)

Generalized Tonic-Clonic Seizures

Chronic Pain

Helps manage Pain

Bipolar 1 Disorder

Mixed manic depressive episode

Acute Mania

Trigeminal Neuralgia (TN)

Helps manage Trigeminal Neuralgia (TN)

Partial-Onset Seizures

Seizures

Seizures

Effectiveness

How Equetro Affects Patients

Carbamazepine is a drug used to treat seizures and facial nerve pain. It has also been found to reduce symptoms of bipolar disorder. Be aware that this drug has a small safety margin, so it is important to take the right dose. Additionally, some people with a certain genetic makeup (the HLA-B*1502 gene) can be more likely to suffer from skin reactions if they take this drug.

How Equetro works in the body

Carbamazepine is used to treat seizures and bipolar disorder. Its exact mechanism is not fully understood, but it is thought to work by limiting the activity of nerve cells and decreasing pain signals in the brain. It works by binding to sodium channels and preventing action potentials, which stop the nerve from firing. In some cases, resistance to this drug can occur due to changes in metabolism caused by certain genotypes.

When to interrupt dosage

The prescribed measure of Equetro is subject to the identified condition, like Partial Seizures With Secondary Generalization, Bipolar Disorder and Trigeminal Neuralgia. The magnitude of dosage fluctuates as per the methodology of delivery featured in the table beneath.

Condition

Dosage

Administration

Common Cold

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Trigeminal Neuralgia

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Seizures

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Syndrome

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Restless Legs Syndrome

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Bipolar Disorder

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Chronic Pain

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Bipolar Disorder

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Seizures

, 100.0 mg, 200.0 mg, 400.0 mg, 300.0 mg, 100.0 mg/mL, 20.0 mg/mL, 10.0 mg/mL

, Tablet, extended release - Oral, Tablet, extended release, Oral, Tablet, chewable - Oral, Tablet, Tablet - Oral, Tablet, chewable, Capsule, extended release, Capsule, extended release - Oral, Injection, powder, for solution, Intravenous, Injection, powder, for solution - Intravenous, Solution - Oral, Solution, Suspension - Oral, Suspension

Warnings

Equetro Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Bone Marrow

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Carbamazepine may interact with Pulse Frequency

There are 20 known major drug interactions with Equetro.

Common Equetro Drug Interactions

Drug Name

Risk Level

Description

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be increased when combined with Carbamazepine.

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Carbamazepine is combined with 2-Methoxyethanol.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Carbamazepine.

5-androstenedione

Major

The metabolism of 5-androstenedione can be increased when combined with Carbamazepine.

7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

Major

The risk or severity of adverse effects can be increased when Carbamazepine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.

Equetro Toxicity & Overdose Risk

The lowest toxic dose of carbamazepine is 1920 mg/kg for women and 54 mg/kg for men. Signs and symptoms of an overdose on carbamazepine usually start to appear between 1-3 hours after ingestion and can include neuromuscular symptoms, cardiovascular effects, restlessness, tremor, dilated pupils, nystagmus, nausea, vomiting, urinary retention, dizziness, or drowsiness. Hyperreflexia or hyporeflexia may also occur. If you think you have overdosed on carbamazepine, contact your local poison control center and seek medical help. Make sure

Equetro Novel Uses: Which Conditions Have a Clinical Trial Featuring Equetro?

179 active clinical trials are being conducted to investigate the potential of Equetro to manage Partial Seizures With Secondary Generalization, Trigeminal Neuralgia and Restless Legs Syndrome (RLS).

Condition

Clinical Trials

Trial Phases

Chronic Pain

124 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Bipolar Disorder

0 Actively Recruiting

Seizures

0 Actively Recruiting

Restless Legs Syndrome

3 Actively Recruiting

Not Applicable

Bipolar Disorder

0 Actively Recruiting

Seizures

5 Actively Recruiting

Phase 3, Phase 2, Phase 1

Trigeminal Neuralgia

0 Actively Recruiting

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Common Cold

0 Actively Recruiting

Equetro Reviews: What are patients saying about Equetro?

5

Patient Review

10/16/2014

Equetro for Bipolar Disorder in Remission

This medication is easy to take and it really helps with my mood swings. The only downside is that it affects my sodium levels.

5

Patient Review

2/14/2011

Equetro for Bipolar I Disorder with Most Recent Episode Mixed

This medication has quickly and effectively helped me with my bipolar disorder. I've only been taking it for a month, and I'm already seeing great results. The side effects are manageable, too; when I first started taking it, I was a little tired, but that went away after a week or two.

5

Patient Review

10/27/2008

Equetro for Bipolar Disorder in Remission

This medication has been incredibly effective for me. I haven't had a single manic episode since starting it, and I couldn't be happier with the results.

5

Patient Review

7/17/2010

Equetro for Facial Nerve Pain

This drug helped me to achieve a better mood, though I did experience constipation as a side effect.

5

Patient Review

2/5/2008

Equetro for Bipolar Disorder in Remission

4.3

Patient Review

5/3/2010

Equetro for Bipolar I Disorder with Most Recent Episode Mixed

My daughter has been on this medication since June, and it has done wonders for her. She loves being on it because she says she feels better now; remembers to take it every day all by herself. The only two problems we've encountered are weight gain and one episode of dizziness when we were increasing her dosage (we decreased the dosage again and that solved the issue). Otherwise, we've been problem-free. YAY!

4.3

Patient Review

6/19/2010

Equetro for Bipolar I Disorder with Most Recent Episode Mixed

This drug has been a total game-changer for me. It's helped limit my bipolar episodes significantly. If I miss even just one dosage, I start having racing thoughts of catastrophe within hours.

4

Patient Review

11/24/2007

Equetro for Mania associated with Bipolar Disorder

3.7

Patient Review

9/23/2014

Equetro for Nerve Pain

I've tried more than 30 different medications for my rapid cycle bipolar disorder, and this is the only one that's worked for me. I was a little tired when increasing dosages, but it's been worth it because my mood swings have decreased, reading thoughts have decreased, depression has decreased, mania has decreased.

2

Patient Review

12/1/2017

Equetro for Mania associated with Bipolar Disorder

I was started on 100mg at bedtime by my PDoc. I've been taking it for two weeks now, and she wanted to get me up to 200mg within that time; however, I found that I was wide awake until 2-3am after only four days. As a result, I'm going to try taking the medication in the morning instead.

Patient Q&A Section about equetro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Equetro prescribed for?

"Equetro is an anticonvulsant medication used to treat seizures and nerve pain such as trigeminal neuralgia and diabetic neuropathy. Equetro is also used to treat bipolar disorder."

Answered by AI

What are the side effects of Equetro?

"This effect is harmless because your body has already absorbed the medication.

You may experience nausea, vomiting, dizziness, drowsiness, constipation, dry mouth, or unsteadiness. If you experience any of these effects for an extended period of time, or if they worsen, talk to your doctor or pharmacist. It is normal for an empty tablet shell to appear in your stool, as your body has already absorbed the medication."

Answered by AI

Is Equetro the same as carbamazepine?

"Equetro is a medication used to treat bipolar disorder. It comes in the form of extended-release capsules of 100 mg, 200 mg, or 300 mg of carbamazepine. Carbamazepine is an anticonvulsant that works by decreasing nerve impulses that cause seizures and pain."

Answered by AI

Is there a generic for Equetro?

"Currently, there is no therapeutically equivalent version of Equetro available for purchase in the United States. It is important to note that some online pharmacies may attempt to sell illegal generic versions of Equetro. These medications may be counterfeit and could pose serious health risks."

Answered by AI

Clinical Trials for Equetro

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Equetro clinical trials?

We made a collection of clinical trials featuring Equetro, we think they might fit your search criteria.
Go to Trials

Have you considered Equetro clinical trials?

We made a collection of clinical trials featuring Equetro, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

Lidocaine Infusions for Postoperative Pain

18+
All Sexes
Nashville, TN

The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major abdominal surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).

Phase 4
Waitlist Available

Vanderbilt University Medical Center

Danial Shams, MD

Image of Baylor College of Medicine/Texas Children's Hospital in Austin, United States.

Guided Imagery Therapy for Abdominal Pain

7 - 12
All Sexes
Austin, TX

Chronic abdominal pain is common among children, and the majority of cases are attributed to functional abdominal pain disorders. One approach to treating these disorders is by using psychological therapies. This clinical trial aims to see how well pre-recorded guided imagery therapy sessions help children's abdominal pain when delivered via a mobile application (app) on a smartphone or tablet. Participants will complete a baseline abdominal pain and stooling diary to determine eligibility, as well as other surveys. Eligible participants will be given access to the guided imagery therapy mobile application. This intervention asks participants to listen to a 10- to 15-minute GIT session 5 out of 7 days per week for 8 weeks, in addition to their usual care for their abdominal pain. Then, participants will complete another abdominal pain and stooling diary, along with other psychometric surveys, at the end of this intervention period. Participants will also collect another diary and surveys 3 months post-treatment.

Waitlist Available
Has No Placebo

Baylor College of Medicine/Texas Children's Hospital (+1 Sites)

Have you considered Equetro clinical trials?

We made a collection of clinical trials featuring Equetro, we think they might fit your search criteria.
Go to Trials